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1. Introduction
Almost six decades ago, a visionary scientist reported a new
method for encapsulating aqueous solutions of protein within
semipermeable polymer membranes [1]. This approach was
successfully tested in the 1970s and 1980s by immobilizing
xenograft islet cells to control glucose metabolism in small
animal models [2,3]. Since then, the concept of cell-laden
hydrogels has evolved and progressed but still those pioneer-
ing works are perfect examples of the theoretical advantages
that this approach may offer in terms of long-term delivery
and immune protection [4].
In its most basic form, cell-laden hydrogels or bioartificial
organs consist of a polymeric or synthetic membrane structure
that entraps a wide range of cells releasing bioactive drugs or
proteins [5,6]. The three-dimensional (3D) constructs, typically
either shaped as a microcapsule or a hollow-fiber, will regulate
with different efficiency the permeability and mechanical sta-
bility of the cell-based medicine [7]. The semipermeable mem-
brane is responsible for preventing high molecular weight
molecules, antibodies and other immunologic components
from entering within the construct but also controls the
inward/outward diffusion of critical agents for cell survival
and therapeutic efficacy including nutrients, oxygen, waste
agents and therapeutic protein products (Figure 1). Even
though the journey from theory to practice has been demand-
ing and challenging, recent progress in the field is creating
new avenues of hope to use this approach in several unmet
clinical needs ranging from diabetes to ophthalmological dis-
orders or rare diseases.
2. Advances in cell-laden hydrogels
Developing an optimized, cell-laden hydrogel with excellent
biocompatibility, mechanical stability, permeability, lack of fibro-
tic overgrowth and the ability to create an appropriate 3D
environment for the enclosed cells is one of the holy grails in
the field. In the search for better biomaterials, many types of
natural and synthetic materials have been explored, with algi-
nates the most frequently employed biomaterial for cell-laden
hydrogels-based spheres. Alginate is a polysaccharide that lines
the cell walls of brown algae. When combined with water, algi-
nate can also be made into a gel that safely encapsulates cells
without limiting function [8–10]. Recently, the MIT-based Sigilon
Therapeutics, developed a new type of cell-loaded capsule
coated by a chemically modify alginate known as Afibromer
[11]. To do so, they attached different molecules to the alginate’s
polymer chain, chemically modifying the structure multiple
times until they found a material that rendered the enclosed
cells invisible to the immune system [12]. This polymer could also
be modified as a coating for implanted medical devices, such as
coronary stents or insulin pumps.
The company has recently partnered with pharmaceutical
Eli Lilly and Company to develop ‘living drug factories’ for
patients with type 1 diabetes. However, though promising,
there are still several important challenges including batch
to batch reproducibility, type of crosslinking ions, smoothness
and charge of the surface of the capsules, type of microen-
capsulation technology and the particularly large diameter of
the reported capsules.
3. Cell candidates
The choice of cell type to interface with the encapsulating
biomaterial is critical. To date, the most successful approaches
to cell therapy have involved the use of mature or adult cell
lines. For cell encapsulation purposes, recombinant clonal
ARPE-19 cell lines have been developed and are currently in
various stages of clinical evaluation for sustained and local
delivery of proteins to both the eye (retinitis pigmentosa,
wet AMD) and brain (Alzheimer’s). A major challenge of this
approach is the development of a system capable of sustained
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and predictable dosing with acceptable cell viability and high,
controlled secretion. Neurotech USA appears to have made
considerable progress along these lines and recently reported
that intravitreal implants of CNTF secreting ARPE-19 cells slo-
wed the progression of retinal degeneration in patients with
macular telangiectasia type 2 [13].
More recent efforts have focused on the development of non-
adult stem cells lines including embryonic (ESC) and induced
pluripotent stem cell lines (iPS) given the holy grail promise of
and infinite supply of an unlimited repertoire of cell types.
Contemporary examples include ViaCyte, inc which is developing
both encapsulated (PEC-Encap system) and non-encapsulated ES-
based beta cell transplants for diabetes [14]. The cells are partially
differentiated prior to subcutaneous implantation where further
in vivo differentiation occurs to the point of insulin secretion.
ViaCyte has also recently announced a strategic collaboration
with CRISPR Therapeutics, inc [15] to work on the fascinating
possibility of creating pancreatic cells that are immunologically
‘invisible’. Interestingly, Semma Therapeutics is also developing
pancreatic stem cells but these cells are more fully differentiated
into cells capable of insulin secretion in response to glucose prior
to encapsulation and implantation.
The development of iPS cells is further behind and both the
ESC and iPS approaches will ultimately need to overcome
obstacles associated with complex, multi-step differentiation
protocols that control cell composition and biological function
and must be integrated with optimal encapsulation, dosing,
and surgical implantation. Despite these challenges, it is pos-
sible that in hindsight we will recognize these advancements
as a turning point in cell encapsulation therapy.
4. Towards clinical translation
Traditionally, advancements in cell encapsulation have been
made in academic research institutions with few industrial
efforts. In the last decade, though, there has been a notable
surge in corporate efforts toward developing and commer-
cializing encapsulated cell products. These efforts have been
largely focused on diabetes with companies such as ViaCyte,
Sernova, Semma Therapeutics, and Sigilon developing var-
ious approaches to islet cell transplantation. Additionally,
continued efforts are ongoing in other therapeutic areas
including ophthalmic and CNS indications. Neurotech
recently described the results of a randomized Phase 2 trial
in which invitreal implantation of CNTF secreting encapsu-
lated cells slowed retinal degeneration in patients with
MacTel type 2 [13]. Neurotech has also reported that the
FDA has granted fast track designation for this approach
[16]. Using a similar approach, Gloriana Therapeutics
recently reported that encapsulated cells secreting GDNF
reduced both behavioral and electrophysiological seizures
as well as epilepsy-related anatomical changes when
implanted into the hippocampus of epileptic rats [17].
Similar devices were neuroprotective in an excitotoxic rat
model of Huntington’s disease [18]. These recent reports not
only support the basic concepts of cell encapsulation but
also bode well for the use of these technologies in a wide
range of human conditions. Last but not least, the new
emerging New-York-based CapCell Biologics is developing
new living implants that will include a proprietary human
cell line engineered to over produce and secrete an
Figure 1. The guidance of therapeutic products by cell-laden hydrogels. The cells are encapsulated in the practical three-dimensional environment with the
selectively permeable frontier. This boundary protects the cell against the antibodies and immune cells while enabling the entrance and the exit of nutrient, oxygen
and therapeutic products, respectively.
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a-galactosidase A analog in a collagen-based hydrogel with
pro-vascular and cell sustaining properties.
5. Expert opinion
Cell therapy has always seemed like an inherently appealing
means of treating a myriad of life-threatening diseases.
However, the complexity of controlling and maintaining the
function of transplanted cells has been difficult to overcome.
High levels of variability have been challenging obstacles
requiring decades long sequential studies to identify the
sources and devise counter strategies. We believe that the
convergence of material sciences, genetic engineering, and
cell biology has pushed the prospects of cellular encapsula-
tion to the forefront of clinically viable cell therapy
approaches [19]. Current clinical trials, largely in diabetes,
have provided an unprecedented optimism and the next
several years could be breakthrough times. This optimism is
based largely on the growing ability to control the inherent
variability mentioned above. On a cellular basis, this is man-
ifested in the ability to controllably differentiate cells and
tissues on large scales. New technologies including CRISPR
will further allow us to control cell viability and function by
eliminating immunological targets within encapsulated cells
or producing cells with greater tolerance to various trans-
plantation sites. On a materials level, manipulating the basic
chemistry of the encapsulation material will likely further
perfect the ability to avoid cellular inflammatory responses.
Finally, technologies including, but not limited to, 3D print-
ing, droplet extrusion, microfluidics, and laser molding will
be increasingly incorporated into clinical development plans
[20,21]. Ultimately, these approaches will converge creating
a gestalt with each individual technology becoming more
powerful than when used alone. We hypothesize that over
the next 10 years this new era will be characterized by
significant improvements in manufacturing control, reduc-
tions in biological variability, and greater clinical control.
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